Animal Trial Begins for Herpes Keratitis Drug Study

[Evaluate]

http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-for-ocular-testing-of-its-drug-candidates-for-the-treatment-of-herpes-keratitis-with-the-baylor-college-of-medicine-300220439.html

Quote

SHELTON, Conn., Feb. 16, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC (the "Company") announced today that it has entered into an agreement with Baylor College of Medicine (Baylor) for the testing of its nanoviricides® drug candidates in a small animal model of ocular virus infections.

The research will be supervised by Dr. Stephen Pflugfelder, Professor of Ophthalmology and the James and Margaret Elkins Chair in Ophthalmology at Baylor. Dr. Pflugfelder has extensive experience in ophthalmological research as well as in ocular drug development, including conducting clinical trials. The research will be performed in the laboratories of the Department of Ophthalmology.

These animal studies will evaluate the efficacy and potency of the Company's nanoviricides anti-viral agents in certain ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of certain ocular viral diseases including herpes keratitis in humans.

"We are very pleased to have the Baylor College of Medicine Department of Ophthalmology join our efforts in developing a drug against ocular viral infections including Herpes Keratitis," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "We believe Dr. Pflugfelder and his lab will be able to guide us in the IND-enabling development of our drug candidates."

About NanoViricides: 
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

 

[HC-Support-Team]

Thanks for sharing Evaluate

[bayern77]

How long does it take to complete phase 1? 

[mcmich]

Nanobio has the same type of cream and finished Phase 3 trials....was licensed by GSK (Glaxo Smith Kline) and it quietly died. was suppose to be the next Abreeva. Not sure why. Google NB-001.

 

Edited March 2, 2016 by mcmich

[fixme1]

20 hours ago, mcmich said:

Nanobio has the same type of cream and finished Phase 3 trials....was licensed by GSK (Glaxo Smith Kline) and it quietly died. was suppose to be the next Abreeva. Not sure why. Google NB-001.

 

Probably cause GSK make profit from anti viral tablets , A main supplier that dont support any vaccine attempts when they have alot of money to make from it(i think they even had failed trails of one). bit strange, maby they like the profit from anti virals long term

Edited March 3, 2016 by fixme1